Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD - PubMed
7 hours ago
- #SLCO4C1
- #cAMP
- #MASLD
- SLCO4C1 is identified as a cAMP uptake transporter in hepatocytes, playing a role in inhibiting lipogenesis.
- The study highlights SLCO4C1 as a potential therapeutic target for Metabolic dysfunction-associated steatotic liver disease (MASLD).
- SLCO4C1's function is dependent on Gln463 and suppresses lipogenesis via the PKA-CREB-SREBP1 pathway.
- Hepatocyte-specific delivery of Slco4c1 via AAV8-TBG increased hepatic cAMP levels, improving MASLD symptoms in male mice.
- Forskolin, which elevates cAMP, also showed potential in alleviating MASLD progression.
- FGF21 upregulates hepatic Slco4c1 expression through ERK/MAPK signaling, involving EGR1 binding to the Slco4c1 promoter.